Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Files for IPO on Euronext Amsterdam Exchange

NEW YORK (GenomeWeb News) - BG Medicine today said it has filed for an initial public offering of its shares on the Euronext Amsterdam Exchange.
 
The biomarker and diagnostics developer said it has filed a registration statement with the US Securities and Exchange Commission but has not yet determined the number of shares it plans to issue and it has not set an opening price for its common stock.
 
BG Medicine said it plans to trade on the Euronext Amsterdam market by the New York Stock Exchange's Euronext under the symbol BGMDX.
 
Cowen International and Fortis will serve as global coordinators and book-runners and Leerink Swann & Co. will co-manage the offering.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.